AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
U.S. Stocks Rally to Record Highs as AI Rebound Fuels Holiday-Shortened Session 
Japan Approves Record ¥122.3 Trillion Budget as Takaichi Seeks Fiscal Balance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index 
Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
Gold and Silver Hit Record Highs as Safe-Haven Demand Surges Amid Global Uncertainty 
Oil Prices Rise on Venezuela Sanctions and Nigeria Airstrikes Despite Annual Losses 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Asian Stocks and Gold Rally as Investors Chase Year-End Gains Amid Dollar Weakness 
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
